Émilie Bortolussi-Courval

Émilie Bortolussi-Courval

Auto-generated profile, based on publicly available information

Émilie Bortolussi-Courval

Division of Experimental Medicine, Department of Medicine, McGill University , Montreal, Quebec

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2024 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
JHJean‐François Huon
Jean‐François Huon
CSChiranjeev Sanyal
Chiranjeev Sanyal
CGCamille L. Gagnon
Camille L. Gagnon
JTJustin Turner
Justin Turner
NKNinh B. Khuong
Ninh B. Khuong
EMEmily G. McDonald
Emily G. McDonald
Background: Potentially inappropriate medications (PIMs) are medications whereby the harms may outweigh the benefits for a given individual. Although overprescribed to older adults, their direct costs on the healthcare system are poorly described. Methods: This was a cross‐sectional study of the cost of PIMs for Canadians aged 65 and older, using adapted criteria from the American Geriatrics Society. We examined prescription claims information from the National Prescription Drug Utilization Information System in 2021 and compared these with 2013. The overall levels of inflation‐adjusted total annual expenditure on PIMs, average cost per quarterly exposure, and average quarterly exposures to PIMs were calculated in CAD$. Results: Exposure to most categories of PIMs decreased, aside from gabapentinoids, proton pump inhibitors, and antipsychotics, all of which increased. Canadians spent $1 billion on PIMs in 2021, a 33.6% reduction compared with 2013 ($1.5 billion). In 2021, the largest annual expenditures were on proton pump inhibitors ($211 million) and gabapentinoids ($126 million). The quarterly amount spent on PIMs per person exposed decreased from $95 to $57. In terms of mean cost per person, opioids and antipsychotics were highest ($138 and $118 per exposure). Some cost savings may have occurred secondary to an observed decline of 16.4% in the quarterly rate of exposure to PIMs (from 7301 per 10,000 in 2013 to 6106 per 10,000 in 2021). Conclusions: While expenditures on PIMs have declined in Canada, the overall cost remains high. Prescribing of some seriously harmful classes of PIMs has increased and so directed, scalable interventions are needed.

26 November 2022 in Journal of the American Geriatrics Society
Verified
Journal Article
Closed access
HAHaris Akhtar
Haris Akhtar
SCShazia H. Chaudhry
Shazia H. Chaudhry
ÉBÉmilie Bortolussi‐Courval
Émilie Bortolussi‐Courval
RHRyan Hanula
Ryan Hanula
AAAnas Akhtar
Anas Akhtar
EMEmily G. McDonald
Emily G. McDonald

28 March 2025 in Journal of the American Geriatrics Society
Verified
Journal Article
Open access
JLJimin J. Lee
Jimin J. Lee
ÉBÉmilie Bortolussi‐Courval
Émilie Bortolussi‐Courval
EFEva Filosa
Eva Filosa
SRSoham Rej
Soham Rej
CGClaire Godard‐Sebillotte
Claire Godard‐Sebillotte
EMEmily G. McDonald
Emily G. McDonald
Background: Polypharmacy is a major risk factor for adverse drug events (ADEs), which are a common cause of hospitalization, especially among older adults. Deprescribing is a promising strategy to prevent ADEs; however, clinicians may hesitate to deprescribe for fear of causing adverse drug withdrawal events (ADWEs). Collectively, ADWEs are the re‐emergence of symptoms or a disease state due to the discontinuation of a medication. Although capturing ADWEs is critical to understanding the complications that might arise from deprescribing, these events may not be routinely or systematically captured in clinical trials. Objectives: We aimed to determine the frequency of ADWE reporting, compare the strengths and limitations of different approaches, and compare the rates of the number of ADWEs detected across trials. Methods: A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses checklist. The search strategy was developed with a research librarian, and studies were identified using Ovid Medline, Embase, and the Cochrane Central Register of Controlled Trials from inception to July 2, 2024. We included all randomized controlled trials testing a deprescribing intervention in older adults (mean or median age ≥ 65 years) and analyzed a subsample of the studies reporting ADWEs as an outcome. Results: Among the 139 eligible studies that were identified, only 12 reported an ADWE. These studies utilized 6 approaches to capture ADWEs: Naranjo ADWE Probability Scale; clinical monitoring for specific withdrawal symptoms; identification through ICD‐10 codes; identification of ADWEs as a subset of confirmed ADEs; patient/caregiver self‐report; and clinical judgment. Conclusion: Results confirmed that few deprescribing studies capture ADWEs and there is a lack of standardized reporting. A harmonized approach to capturing ADWEs with specific criteria could ensure more consistent results in deprescribing trials, improve our understanding of this important outcome, and facilitate future meta‐analyses.

21 March 2024 in Kidney Medicine
Verified
Journal Article
Open access
ÉBÉmilie Bortolussi-Courval
Émilie Bortolussi-Courval
TPTiina Podymow
Tiina Podymow
MBMarisa Battistella
Marisa Battistella
ETEmilie Trinh
Emilie Trinh
TMThomas A. Mavrakanas
Thomas A. Mavrakanas
EMEmily G. McDonald
Emily G. McDonald
Patients treated with dialysis are commonly prescribed multiple medications (polypharmacy), including some potentially inappropriate medications (PIMs). PIMs are associated with an increased risk of medication harm (eg, falls, fractures, hospitalization). Deprescribing is a solution that proposes to stop, reduce, or switch medications to a safer alternative. Although deprescribing pairs well with routine medication reviews, it can be complex and time-consuming. Whether clinical decision support improves the process and increases deprescribing for patients treated with dialysis is unknown. This study aimed to test the efficacy of the clinical decision support software MedSafer at increasing deprescribing for patients treated with dialysis. Prospective controlled quality improvement study with a contemporaneous control. Patients prescribed ≥5 medications in 2 outpatient dialysis units in Montréal, Canada. Patient health data from the electronic medical record were input into the MedSafer web-based portal to generate reports listing candidate PIMs for deprescribing. At the time of a planned biannual medication review (usual care), treating nephrologists in the intervention unit additionally received deprescribing reports, and patients received EMPOWER brochures containing safety information on PIMs they were prescribed. In the control unit, patients received usual care alone. The proportion of patients with ≥1 PIMs deprescribed was compared between the intervention and control units following a planned medication review to determine the effect of using MedSafer. The absolute risk difference with 95% CI and number needed to treat were calculated. The primary outcome was the proportion of patients with one or more PIMs deprescribed. Secondary outcomes include the reduction in the mean number of prescribed drugs and PIMs from baseline. In total, 195 patients were included (127, control unit; 68, intervention unit); the mean age was 64.8 ± 15.9 (SD), and 36.9% were women. The proportion of patients with ≥1 PIMs deprescribed in the control unit was 3.1% (4/127) vs 39.7% (27/68) in the intervention unit (absolute risk difference, 36.6%; 95% CI, 24.5%-48.6%; P < 0.0001; number needed to treat = 3). This was a single-center nonrandomized study with a type 1 error risk. Deprescribing durability was not assessed, and the study was not powered to reduce adverse drug events. Deprescribing clinical decision support and patient EMPOWER brochures provided during medication reviews could be an effective and scalable intervention to address PIMs in the dialysis population. A confirmatory randomized controlled trial is needed.

7 September 2023 in PLOS Global Public Health
Verified
Journal Article
Open access
PDF file
ÉBÉmilie Bortolussi-Courval
Émilie Bortolussi-Courval
NSNatalie Stake-Doucet
Natalie Stake-Doucet
BUBirgit Umaigba
Birgit Umaigba
In recent months, to palliate against a shortage of nurses, several high-income countries (HICs) have turned to low and middle-income countries (LMICs) to recruit nurses to their healthcare systems, despite the global nursing shortage disproportionately affecting LMICs [1]. This approach is ill-conceived. High-income countries do not have a shortage of registered nurses (RNs); they have a shortage of healthcare institutions providing necessary and sustainable working conditions, leading to a loss of nurses [2]. In Canada, the number of vacant RN positions increased from 10,400 to 22,400 (85.8%) from 2019-2021, despite a net growth of 7910 nurses (+2.5%) from 2020-2021 [3]. Rather than resorting to recruiting nurses overseas, governments should implement other solutions with documented success: safe nurse-patient ratios and measures to protect nurses from structural and workplace violence.

26 June 2023 in Canadian Journal of Kidney Health and Disease
Verified
Journal Article
Open access
ÉBÉmilie Bortolussi-Courval
Émilie Bortolussi-Courval
TPTiina Podymow
Tiina Podymow
ETEmilie Trinh
Emilie Trinh
JMJoseph Moryousef
Joseph Moryousef
RHR. Hanula
R. Hanula
EMEmily Gibson McDonald
Emily Gibson McDonald
Background: Patients on dialysis are commonly prescribed multiple medications (polypharmacy), many of which are potentially inappropriate medications (PIMs). Potentially inappropriate medications are associated with an increased risk of falls, fractures, and hospitalization. MedSafer is an electronic tool that generates individualized, prioritized reports with deprescribing opportunities by cross-referencing patient health data and medications with guidelines for deprescribing. Objectives: Our primary aim was to increase deprescribing, as compared with usual care (medication reconciliation or MedRec), for outpatients receiving maintenance hemodialysis, through the provision of MedSafer deprescribing opportunity reports to the treating team and patient empowerment deprescribing brochures provided directly to the patients themselves. Design: This controlled, prospective, quality improvement study with a contemporary control builds on existing policy at the outpatient hemodialysis centers where biannual MedRecs are performed by the treating nephrologist and nursing team. Setting: The study takes place on 2 of the 3 outpatient hemodialysis units of the McGill University Health Centre in Montreal, Quebec, Canada. The intervention unit is the Lachine Hospital, and the control unit is the Montreal General Hospital. Patients: A closed cohort of outpatient hemodialysis patients visit one of the hemodialysis centers multiple times per week for their hemodialysis treatment. The initial cohort of the intervention unit includes 85 patients, whereas the control unit has 153 patients. Patients who are transplanted, hospitalized during their scheduled MedRec, or die before or during the MedRec will be excluded from the study. Measurements: We will compare rates of deprescribing between the control and intervention units following a single MedRec. On the intervention unit, MedRecs will be paired with MedSafer reports (the intervention), and on the control unit, MedRecs will take place without MedSafer reports (usual care). On the intervention unit, patients will also receive deprescribing patient empowerment brochures for select medication classes (gabapentinoids, proton-pump inhibitors, sedative hypnotics and opioids for chronic non-cancer pain). Physicians on the intervention unit will be interviewed post-MedRec to determine implementation barriers and facilitators. Methods: The primary outcome will be the proportion of patients with 1 or more PIMs deprescribed on the intervention unit, as compared with the control unit, following a biannual MedRec. This study will build on existing policies aimed at optimizing medication therapy in patients undergoing maintenance hemodialysis. The electronic deprescribing decision support tool, MedSafer, will be tested in a dialysis setting, where nephrologists are regularly in contact with patients. MedRecs are an interdisciplinary clinical activity performed biannually on the hemodialysis units (in the Spring and Fall), and within 1 week following discharge from any hospitalization. This study will take place in the Fall of 2022. Semi-structured interviews will be conducted among physicians on the intervention unit to determine barriers and facilitators to implementation of the MedSafer-supplemented MedRec process and analyzed according to grounded theory in qualitative research. Limitations: Deprescribing can be limited due to nephrologists’ time constraints, cognitive impairment of the hemodialyzed patient stemming from their illness and complex medication regimens, and lack of sufficient patient resources to learn about the medications they are taking and their potential harms. Conclusions: Electronic decision support can facilitate deprescribing for the clinical team by providing a nudge reminder, decreasing the time it takes to review and effectuate guideline recommendations, and by lowering the barrier of when and how to taper. Guidelines for deprescribing in the dialysis population have recently been published and incorporated into the MedSafer software. To our knowledge, this will be the first study to examine the efficacy of pairing these guidelines with MedRecs by leveraging electronic decision support in the outpatient dialysis population. Trial registration: This study was registered on Clinicaltrials.gov (NCT05585268) on October 2, 2022, prior to the enrolment of the first participant on October 3, 2022. The registration number is pending at the time of protocol submission.